Glenmark Pharma Q3 Result 2024: Date and Time, Share Price and Target

News: Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, is set to announce its Q3 2024 financial results. Investors and stakeholders eagerly await this update to assess the company’s performance. In this article, we’ll cover the key details you need to know about Glenmark Pharma’s Q3 results.

1. Date and Time of Announcement

The Q3 2024 earnings release is scheduled for February 13, 2024. Mark your calendars! On this day, Glenmark Pharma will unveil its financial performance for the third quarter of the fiscal year.

2. Share Price Movement

As of the latest data, Glenmark Pharmaceuticals’ share price stands at 910.2 INR. Investors will closely monitor any fluctuations in the stock price following the earnings announcement. Keep an eye on the market to see how investors react to the Q3 results.

3. Target Analysis

Financial analysts have estimated an average target price of 690.17 INR for Glenmark Pharma. This consensus estimate suggests a potential downside of approximately 19.61% from the current share price. However, it’s essential to remember that stock prices can be influenced by various factors, including market sentiment, industry trends, and company-specific news.

Be in the know with Sarkari Result! Keep abreast of the latest celebrity happenings and get insightful movie analysis. Engage fully with the ever-changing entertainment industry with Sarkari Exam.

Founding and Evolution

• Glenmark was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer.
• The company’s name is a tribute to Saldanha’s two sons.
• Initially, Glenmark sold its products in India, Russia, and Africa.

Global Presence

• Glenmark has 87 local offices in over 50 countries worldwide.
• With 15,000+ dedicated employees, including 1,400+ in research and development (R&D), Glenmark operates across the globe.
• The company boasts 14 manufacturing facilities and 4 state-of-the-art R&D centers.

Business Segments

1. Branded Generics: Glenmark’s branded generics business has a significant presence in emerging economies, including India.
2. API Business: The active pharmaceutical ingredient (API) business sells products in over 65 countries, including the US, various EU countries, South America, and India.

Financial Insights

• Glenmark ranks among the World’s Top 100 Biopharmaceutical companies and the Top 50 Generics and Biosimilars Companies.
• Analysts estimate an average target price of 690.17 INR for Glenmark Pharma, suggesting a potential downside of approximately 19.61% from the current share price.

Investors, analysts, and industry watchers eagerly await Glenmark Pharma’s Q3 results. Stay tuned for the official announcement on February 13, 2024, and keep an eye on the stock market to gauge the impact on share prices. Remember that investing involves risks, and it’s essential to make informed decisions based on thorough research and analysis.

Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.